Skip to main
  1. Stocks
  2. Carlsmed Inc
  3. Forecast
CARL

Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed Inc (CARL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Carlsmed is demonstrating a strong fundamental growth profile, with 3Q26 revenue of about $21.6M up 64.9% year over year, active surgeons growing more than 60%, and utilization rising to roughly 5.7 devices per surgeon, showing both new-customer acquisition and deeper penetration of the existing base. Its outlook is further strengthened by aprevo Cervical reaching about 12% of revenue in its second full quarter, improving gross margins to 77.3%, and a cash position of $80M alongside $15M of debt, suggesting the business is scaling with manageable balance-sheet risk. The investment case is reinforced by raised FY26 revenue guidance of $78M to $80M, the October 2026 reimbursement-driven DRG changes that should support higher payment categories, and upcoming product launches that can expand average selling prices and operating leverage.

Bears say

Carlsmed is facing a fundamentally fragile growth path because its upside depends on rapid surgeon adoption of aprevo, yet downside risks include fewer new surgeons than modeled, slower overall spine market growth, and faster average selling price degradation. The company also appears exposed to execution and market-structure risks, including poor sales execution, increasing competition in spine, reimbursement headwinds, and delayed entry into the cervical spine market, any of which could slow commercial momentum. Under a bear case, revenue growth is expected to decelerate to 10-20% over the modeling horizon with slower progress toward profitability, while higher operating expense spend could further pressure margins and delay a durable earnings inflection.

Carlsmed Inc (CARL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Carlsmed Inc and is not a guaranteed prediction by Public.com or investment advice.

Carlsmed Inc (CARL) Analyst Forecast & Price Prediction

Get the latest Carlsmed Inc (CARL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Carlsmed Inc (CARL)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Carlsmed Inc (CARL) Forecast

Analysts have given Carlsmed Inc (CARL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Carlsmed Inc (CARL) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Carlsmed Inc (CARL)


Carlsmed Inc (CARL) Analyst Forecast & Price Prediction

Get the latest Carlsmed Inc (CARL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Carlsmed Inc (CARL)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CARL stock data and trends